
Hologic (HOLX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.0B
Gross Profit
377.3M
37.53%
Operating Income
37.9M
3.77%
Net Income
-17.4M
-1.73%
EPS (Diluted)
$-0.08
Balance Sheet Metrics
Total Assets
8.5B
Total Liabilities
3.9B
Shareholders Equity
4.6B
Debt to Equity
0.85
Cash Flow Metrics
Operating Cash Flow
28.4M
Free Cash Flow
129.2M
Revenue & Profitability Trend
Hologic Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 4.0B | 4.0B | 4.9B | 5.6B | 3.8B |
Cost of Goods Sold | 1.8B | 2.0B | 1.9B | 1.8B | 1.5B |
Gross Profit | 2.2B | 2.1B | 3.0B | 3.8B | 2.2B |
Gross Margin % | 55.3% | 51.4% | 61.6% | 67.4% | 59.0% |
Operating Expenses | |||||
Research & Development | 272.8M | 294.3M | 283.4M | 276.3M | 222.5M |
Selling, General & Administrative | 994.8M | 987.6M | 1.0B | 994.4M | 840.3M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.3B | 1.3B | 1.3B | 1.3B | 1.1B |
Operating Income | 931.0M | 761.5M | 1.6B | 2.5B | 1.1B |
Operating Margin % | 23.1% | 18.9% | 33.5% | 44.1% | 29.8% |
Non-Operating Items | |||||
Interest Income | 108.7M | 120.5M | 12.9M | 1.4M | 4.3M |
Interest Expense | 122.1M | 111.1M | 95.1M | 93.6M | 116.5M |
Other Non-Operating Income | -52.5M | -94.8M | 39.6M | -29.6M | -10.9M |
Pre-tax Income | 865.1M | 676.1M | 1.6B | 2.4B | 1.0B |
Income Tax | 75.6M | 220.1M | 286.2M | 491.4M | -108.6M |
Effective Tax Rate % | 8.7% | 32.6% | 18.0% | 20.8% | -10.8% |
Net Income | 789.5M | 456.0M | 1.3B | 1.9B | 1.1B |
Net Margin % | 19.6% | 11.3% | 26.8% | 33.2% | 29.4% |
Key Metrics | |||||
EBITDA | 1.3B | 1.2B | 2.1B | 2.9B | 1.5B |
EPS (Basic) | $3.35 | $1.85 | $5.18 | $7.28 | $4.24 |
EPS (Diluted) | $3.32 | $1.83 | $5.13 | $7.21 | $4.21 |
Basic Shares Outstanding | 235723000 | 246772000 | 251527000 | 257046000 | 262727000 |
Diluted Shares Outstanding | 235723000 | 246772000 | 251527000 | 257046000 | 262727000 |
Income Statement Trend
Hologic Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.2B | 2.7B | 2.3B | 1.2B | 701.0M |
Short-term Investments | 173.4M | 0 | - | - | - |
Accounts Receivable | 600.4M | 625.6M | 617.6M | 942.7M | 1.0B |
Inventory | 679.8M | 617.6M | 623.7M | 501.2M | 395.1M |
Other Current Assets | 156.2M | 175.3M | 232.2M | 528.8M | 58.5M |
Total Current Assets | 3.8B | 4.2B | 3.9B | 3.2B | 2.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.0B | 959.0M | 957.7M | 1.0B | 998.2M |
Goodwill | 7.7B | 7.5B | 7.8B | 8.2B | 6.6B |
Intangible Assets | 844.6M | 888.6M | 1.3B | 1.7B | 1.3B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 193.3M | 133.6M | 86.9M | 88.3M | 375.2M |
Total Non-Current Assets | 5.3B | 5.0B | 5.2B | 5.8B | 5.0B |
Total Assets | 9.2B | 9.1B | 9.1B | 8.9B | 7.2B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 203.8M | 175.2M | 197.7M | 215.9M | 178.8M |
Short-term Debt | 64.8M | 310.5M | 41.4M | 343.5M | 350.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | 8.2M | 175.7M | 168.1M | 114.0M |
Total Current Liabilities | 1.0B | 1.2B | 937.7M | 1.3B | 1.2B |
Non-Current Liabilities | |||||
Long-term Debt | 2.6B | 2.6B | 2.9B | 2.8B | 2.8B |
Deferred Tax Liabilities | 371.2M | 294.5M | 342.4M | 460.5M | 305.5M |
Other Non-Current Liabilities | 10.6M | 13.2M | 25.3M | 16.2M | 18.0M |
Total Non-Current Liabilities | 3.0B | 2.9B | 3.3B | 3.4B | 3.2B |
Total Liabilities | 4.0B | 4.1B | 4.2B | 4.7B | 4.5B |
Equity | |||||
Common Stock | 3.0M | 3.0M | 3.0M | 3.0M | 2.9M |
Retained Earnings | 2.8B | 2.1B | 1.6B | 298.3M | -1.6B |
Treasury Stock | 3.9B | 3.0B | 2.5B | 2.0B | 1.6B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 5.1B | 5.0B | 4.9B | 4.2B | 2.7B |
Key Metrics | |||||
Total Debt | 2.7B | 2.9B | 2.9B | 3.1B | 3.1B |
Working Capital | 2.8B | 3.0B | 2.9B | 1.8B | 983.0M |
Balance Sheet Composition
Hologic Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 789.5M | 456.0M | 1.3B | 1.9B | 1.1B |
Depreciation & Amortization | 309.0M | 323.4M | 430.1M | 406.9M | 376.0M |
Stock-Based Compensation | 82.3M | 79.6M | 66.7M | 65.0M | 83.3M |
Working Capital Changes | 25.1M | -15.0M | 109.0M | 61.2M | -442.3M |
Operating Cash Flow | 1.2B | 748.9M | 1.7B | 2.4B | 1.1B |
Investing Activities | |||||
Capital Expenditures | -57.8M | -58.4M | -56.6M | -59.4M | -156.4M |
Acquisitions | -328.6M | -5.0M | -158.6M | -1.2B | 19.9M |
Investment Purchases | -310.2M | -10.0M | 0 | - | -2.4M |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -698.6M | -60.3M | -135.7M | -1.2B | -144.0M |
Financing Activities | |||||
Share Repurchases | -835.1M | -474.8M | -542.1M | -409.8M | -653.6M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 0 | 1.5B | 1.3B | 750.0M |
Debt Repayment | -291.3M | -19.0M | -1.7B | -1.4B | -797.5M |
Financing Cash Flow | -1.1B | -526.2M | -1.0B | -831.1M | -975.5M |
Free Cash Flow | 1.1B | 901.0M | 2.0B | 2.1B | 740.2M |
Net Change in Cash | -663.6M | 162.4M | 561.0M | 321.1M | -59.1M |
Cash Flow Trend
Hologic Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.24
Forward P/E
14.42
Price to Book
3.12
Price to Sales
3.75
PEG Ratio
14.42
Profitability Ratios
Profit Margin
13.79%
Operating Margin
25.48%
Return on Equity
11.38%
Return on Assets
6.69%
Financial Health
Current Ratio
3.56
Debt to Equity
52.09
Beta
0.49
Per Share Data
EPS (TTM)
$2.41
Book Value per Share
$21.79
Revenue per Share
$17.67
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
holx | 15.1B | 28.24 | 3.12 | 11.38% | 13.79% | 52.09 |
Intuitive Surgical | 168.5B | 65.38 | 9.44 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 55.5B | 35.31 | 2.18 | 6.18% | 7.41% | 75.93 |
Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
ResMed | 41.6B | 29.85 | 6.97 | 25.86% | 27.22% | 14.27 |
West Pharmaceutical | 17.3B | 36.05 | 5.92 | 17.72% | 16.48% | 10.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.